Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

This study has been terminated.
(In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs)
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01274559
First received: October 25, 2010
Last updated: July 30, 2014
Last verified: July 2014

October 25, 2010
July 30, 2014
March 2011
February 2013   (final data collection date for primary outcome measure)
Percent Change From Baseline at Week 12 in Low Density Lipoprotein-Cholesterol (LDL-C) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
Percent change from baseline at Week 12 for Low Density Lipoprotein-Cholesterol (LDL-C) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01274559 on ClinicalTrials.gov Archive Site
  • Percent Change From Baseline in LDL-C:High-density Lipoprotein Cholesterol (HDL-C) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in HDL-C at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Triglyceride (TG) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Non-HDL-C at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Apo B:Apolipoprotein A-I (Apo A-I) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Total Cholesterol (TC):HDL-C at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Apo A-I at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in TC at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in LDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in LDL-C:HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in TG at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Non-HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Apo B at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Apo B:Apo A-I at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in TC:HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Lp(a) at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in Apo A-I at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent Change From Baseline in TC at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Number of Participants Who Achieve LDL-C Target Levels at Week 12 of Treatment [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    assessed as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and European Society of Cardiology (ESC) treatment guidelines
  • Percent change from baseline in LDL-C:High-density lipoprotein cholesterol (HDL-C) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in HDL-C at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in triglyceride (TG) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in non-HDL-C at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in apolipoprotein B (Apo B) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in Apo B:apolipoprotein A-I (Apo A-I) at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in total cholesterol (TC):HDL-C at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in lipoprotein a [Lp(a)] at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in Apo A-I at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in TC at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Percent change from baseline in LDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline in LDL-C:HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline in HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline in TG at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline in non-HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline in Apo B at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline Apo B:Apo A-I at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline TC:HDL-C at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline Lp(a) at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline Apo A-I at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Percent change from baseline TC at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
  • Proportion of Participants who achieve LDL-C target levels at Week 12 of treatment [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    assessed as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and European Society of Cardiology (ESC) treatment guidelines
Not Provided
Not Provided
 
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

This is a multicenter, randomized, double-blind, placebo-controlled study in participants with primary hypercholesterolemia or mixed dyslipidemia, and elevated low density lipoprotein-cholesterol (LDL-C) to assess the efficacy and safety of extended release (ER) niacin/laropiprant [ERN/LRPT (MK-0524A)] when added to the following ongoing lipid-modifying therapy (LMT): simvastatin,

atorvastatin, rosuvastatin monotherapy, ezetimibe/simvastatin fixed dose combination (FDC), or any statin co-administered with ezetimibe. The study is based on the hypothesis that ERN/LRPT 2 g daily will be superior to placebo at lowering LDL-C at Week 12 of treatment.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia
  • Drug: Extended-release niacin/laropiprant (ERN/LRPT)
    1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
  • Drug: Placebo
    1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
  • Experimental: Extended-release niacin/laropiprant
    ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
    Intervention: Drug: Extended-release niacin/laropiprant (ERN/LRPT)
  • Placebo Comparator: Placebo
    Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1173
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has a history of primary hypercholesterolemia or mixed dyslipidemia.
  • Must meet one of the risk categories (very high, high or moderate and corresponding LDL-C criteria at Visit 2.
  • Has TG levels <500 mg/dL (<5.65 mmol/L).
  • Has been on a stable dose of one of the following lipid-modifying therapies (LMTs)for at least 6 weeks prior to Visit 1, and agrees to remain on the same type and dose of LMT for the duration of the study:

    • Monotherapy: any statin
    • Combination Therapy: ezetimibe/simvastatin in the same tablet
    • Co-administration Therapy: any statin co-administered with ezetimibe
  • Is male or female and ≥18 years of age on day of signing informed consent.
  • A female must meet ONE of the following:

    • Of reproductive potential and agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control for the study duration.
    • Not of reproductive potential is eligible without requiring the use of contraception. Definition of "not of reproductive potential": one who has either of the following:

      • reached natural menopause, defined as: 6 months of spontaneous amenorrhea with serum FSH levels (at Visit 1) in the postmenopausal range (per central lab) or 12 months of spontaneous amenorrhea.Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa).
      • 6 weeks post surgical hysterectomy, or bilateral oophorectomy with or without hysterectomy.
      • Bilateral tubal ligation without subsequent restorative procedure.
  • Understands the study's procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent.

Exclusion Criteria

- Has taken a prohibited LMT within 6 weeks of Visit 1. Examples of

prohibited LMT include bile acid sequestrants, fibrates (monotherapy, coadministration or combination with other LMT), niacin >50 mg, and red yeast rice products.

  • Has had a change to the type or dose of acceptable LMT regimen within 6 weeks of Visit 1.
  • Is pregnant, breastfeeding, or expecting to conceive during the study including the 14-day poststudy follow-up.
  • Has a history of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Female who is expecting to donate eggs during the study, including the 14-day follow-up.
  • Is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
  • Has participated in a study, including post-study follow-up, with an investigational compound (non-lipid-modifying) within 30 days of Visit 1 or a lipid-modifying compound (investigational or marketed), within 6 weeks of Visit 1.
  • Has donated and/or received blood as follows:

    • donated blood products or has had phlebotomy of >300 mL within 8 weeks prior to signing informed consent.
    • intends to give or receive blood products during the study.
    • intends to donate more than 250 mL of blood products within 8 weeks following the last study visit.
  • Has the following exclusionary laboratory values at Visit 2

    • Creatinine clearance (eGFR) <30 mL/min (0.50 mL/s)
    • ALT (SGPT) >1.5 x ULN
    • AST (SGOT) >1.5 x ULN
    • CK >2 x ULN
  • Has used recreational or illicit drugs within 1 year of signing informed consent.
  • Was <80% compliant with LMT or placebo at Visit 2, AND in the opinion of the investigator, is believed to be unable to maintain at least 80% compliance with dosing during the active treatment period.
  • Has chronic heart failure defined by the New York Heart Association (NYHA) Classes III or IV, uncontrolled cardiac arrhythmias, or poorly controlled hypertension (systolic blood pressure >160 mm Hg or diastolic >100 mm Hg).
  • Has Type 1 or Type 2 diabetes mellitus and meets one or more of the following criteria:

    • Is poorly controlled (HbA1C >8.0% at Visit 1)
    • Is newly diagnosed (within 3 months of Visit 1)
    • Has recently experienced repeated hypoglycemia or unstable glycemic control (within 3 months of Visit 1).
    • Is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of ± ≤ 10 units of insulin) within 3 months of Visit 1.
  • Has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins (i.e., secondary causes of hyperlipidemia such as hyper- or hypothyroidism.
  • Has nephrotic syndrome or other clinically significant renal disease.
  • Has active peptic ulcer disease within 3 months of Visit 1.
  • Has a history of hypersensitivity or allergic reaction to niacin or niacin containing products.
  • Has history of myocardial infarction, stroke, coronary artery bypass surgery or other revascularization procedure, unstable angina or angioplasty within 3 months of Visit 1.
  • Has arterial bleeding.
  • Has a history of ileal bypass, gastric bypass or other significant condition associated with malabsorption or rapid weight loss within 18 months of Visit 1.
  • Has active or chronic hepatobiliary or hepatic disease.
  • Is Chinese and is on simvastatin 80 mg or a product containing simvastatin 80 mg at Visit 1.
  • Is receiving treatment with systemic steroids (intravenous, injected, and oral steroids) OR systemic anabolic agents.
  • Consumes more than 3 alcoholic drinks on any given day or more than 14 drinks per week.
  • Is taking the following antioxidant vitamins each day:

    • Vitamin C in excess of 1500 mg
    • Vitamin E in excess of 45 IU for men, 36 IU for women
    • Beta Carotene 15000 IU for men, 12000 IU for women
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01274559
0524A-133, CTRI/2012/08/002857
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP